Company performance
Add to research
Current Price
as of Apr 22, 2025$105.51
P/E Ratio
275.84
Market Cap
$131.53B
Description
Add to research
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Metrics
Add to research
Overview
- HQFoster City, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerGILD
- Price$105.51+1.13%
Trading Information
- Market cap$131.53B
- Float99.80%
- Average Daily Volume (1m)9,290,834
- Average Daily Volume (3m)9,370,596
- EPS$0.38
Company
- Revenue$28.73B
- Rev growth (1yr)6.17%
- Net income$480.00M
- Gross margin78.24%
- EBITDA margin46.74%
- EBITDA$13.43B
- EV$131.59B
- EV/Revenue4.58
- P/E275.84
- P/S4.61
- P/B6.80
- Debt/Equity141.35
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia